Member Info for Sunningdale1

For those that were interested in my previous message on Open Orph (no worries if you're not) ORPH have very recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of their Genomic Health Data platform and will speed up its launch.

Maurice Treacy highlights the significant value of the genomic health database in a presentation just before the announcement. Huge potential upside here. - "When I talked about the 10,000 data records we hope to collect or corral in our database, each one of those per patient is valued roughly, based on these precedents, at about 5000. So the nominal value of that database is about 50 million. That's just assuming a linear access fee. We hope there will be multiple pharma companies looking at this data at the same time."
https://www.youtube.com/watch?v=XrT6SBVa5F0 (16:36 onwards)

For more info Maurice Treacy is holding a live webinar tomorrow at 19:00 (UK time) https://vtm.clickmeeting.com/orph

For those that were interested in my previous message on Open Orph (no worries if you're not) ORPH have very recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of their Genomic Health Data platform and will speed up its launch.

Maurice Treacy highlights the significant value of the genomic health database in a presentation just before the announcement. Huge potential upside here. - https://www.youtube.com/watch?v=XrT6SBVa5F0 (16:36 onwards)

"When I talked about the 10,000 data records we hope to collect or corral in our database, each one of those per patient is valued roughly, based on these precedents, at about 5000. So the nominal value of that database is about 50 million. That's just assuming a linear access fee. We hope there will be multiple pharma companies looking at this data at the same time."

For more info Maurice Treacy is holding a live webinar tomorrow at 19:00 (UK time) https://vtm.clickmeeting.com/orph

For those that were interested in my previous message on Open Orph (no worries if you're not) ORPH have very recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of their Genomic Health Data platform and will speed up its launch.

Maurice Treacy highlights the significant value of the genomic health database in a presentation just before the announcement. Huge potential upside here. - "When I talked about the 10,000 data records we hope to collect or corral in our database, each one of those per patient is valued roughly, based on these precedents, at about 5000. So the nominal value of that database is about 50 million. That's just assuming a linear access fee. We hope there will be multiple pharma companies looking at this data at the same time."
https://www.youtube.com/watch?v=XrT6SBVa5F0 (16:36 onwards)

For more info Maurice Treacy is holding a live webinar tomorrow at 19:00 (UK time) https://vtm.clickmeeting.com/orph

For those that were interested in my previous message on Open Orph (no worries if you're not) ORPH have very recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of their Genomic Health Data platform and will speed up its launch.

Maurice Treacy highlights the significant value of the genomic health database in a presentation just before the announcement. Huge potential upside here. - "When I talked about the 10,000 data records we hope to collect or corral in our database, each one of those per patient is valued roughly, based on these precedents, at about 5000. So the nominal value of that database is about 50 million. That's just assuming a linear access fee. We hope there will be multiple pharma companies looking at this data at the same time."
https://www.youtube.com/watch?v=XrT6SBVa5F0 (16:36 onwards)

For more info Maurice Treacy is holding a live webinar tomorrow at 19:00 (UK time) https://vtm.clickmeeting.com/orph

Progressing well - should see rise next week with the AGM on Wednesday.

For those interested in alternative Pharma stocks (if you're not, no problem - this is a shameless plug) Open Orphan AIM:ORPH is one I’d recommend keeping an eye on - Share price has performed well over the last 6 months and it's no surprise - CEO Cathal Friel predicts 40% growth a year on podcast below with 2 million of his own money invested. hxxps://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year

Their health databank a standout for me and is progressing well. ORPH recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of Open Orphan’s Genomic Health Data platform and will speed up its launch. The companies CCO Maurice Treacy is holding a live webinar on Wednesday 30th October 2019 at 19:00 (UK time) for those interested: https://vtm.clickmeeting.com/orph

Keep holding, this is one for the long-term. I predict significant upside here over the next 3 years.

For those interested in alternative Pharma stocks (if you're not, no problem - this is a shameless plug) Open Orphan AIM:ORPH is one I’d recommend keeping an eye on - Share price has performed well over the last 6 months and it's no surprise - CEO Cathal Friel predicts 40% growth a year on podcast below with 2 million of his own money invested. hxxps://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year

Their health databank a standout for me and is progressing well. ORPH recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of Open Orphan’s Genomic Health Data platform and will speed up its launch. The companies CCO Maurice Treacy is holding a live webinar on Wednesday 30th October 2019 at 19:00 (UK time) for those interested: https://vtm.clickmeeting.com/orph

Nothing happening IMO unfortunately. For those interested in alternative Pharma stocks (if you're not, no problem - this is a shameless plug) Open Orphan AIM:ORPH is one I’d recommend keeping an eye on - Share price has performed well over the last 6 months and it's no surprise - CEO Cathal Friel predicts 40% growth a year on podcast below with 2 million of his own money invested. hxxps://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year

Their health databank a standout for me and is progressing well. ORPH recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of Open Orphan’s Genomic Health Data platform and will speed up its launch. The companies CCO Maurice Treacy is holding a live webinar on Wednesday 30th October 2019 at 19:00 (UK time) for those interested: https://vtm.clickmeeting.com/orph

All gone a little bit quiet here and share price falling. I wonder when the trial for the second patient cohort / those receiving the higher pre-specified dose of RXC004 will begin? Anson commented results will be released in 2020. Hopefully will see some other news before then to stop this going down.

In the meantime, for those interested in Pharma stocks Open Orphan AIM:ORPH is one I’d recommend keeping an eye on (shameless plug) - CEO Cathal Friel predicts 40% growth a year on recent podcast below with 2 million of his own money invested. https://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year

The company has a four pronged strategy including a European health data collection platform - with patient clinical and genomic data. For measure GSK recently valued an Alzheimers neurologival disorder database for £300m so big money business. CCO Maurice Treacy explains on proactive https://www.youtube.com/watch?v=eFvPcwjL-m4

Nice to see Opti on Zak Mir's bulletin board heroes - solid growth so far this week. Seemed to have turned a corner.

For anyone interested in upcoming health/bio/pharma stocks Open Orphan AIM:ORPH is one to watch - CEO Cathal Friel predicts 40% growth a year on recent podcast below with 2 million of his own money invested. https://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year

The company has a four pronged strategy including a European health data collection platform - with patient clinical and genomic data. For measure GSK recently valued an Alzheimers neurologival disorder database for £300m so big money business. CCO Maurice Treacy explains on proactive https://www.youtube.com/watch?v=eFvPcwjL-m4

Pleased to see Kibo management have stumped up £500k at current sp. Also with the other 1 million underwritten, I am happy to get involved now. Going to speak to First Equity.

Lots of trading today - hoping for things to settle over the month and see some steady incline - For those interested in pharma stocks Open Orphan ORPH is worth keeping an eye on - CEO Cathal Friel shown serious backing with £2 million of his own money in - predicts 40% growth a year on recent podcast https://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year

Half year report indicates minor progress after poor 2018 - 2% increase in gross profit - 14% increase in interim dividend to 2.5p (2018: 2.2p) per share - Cash balances of £13.7m at 30 June 2019 (Dec 2018: £12.9m)
Have fallen victim to ongoing issues outside of their control (African Swine Fever, Brexit) but near-term appears to remain very uncertain - could be a long time before recovery

For those interested in health/bio/pharma stocks also keeping tabs on Open Orphan ORPH - CEO Cathal Friel predicts 40% growth a year with 2 million of his own cash invested. Around 30 million people in Europe suffer rare diseases so huge market. Their health databank a standout for me - GSK recently valued an Alzheimers neurologival disorder data base for £300m. CCO Maurice Treacy helps to explain the value of their patient clinical and genomic database well on recent Proactive interview https://www.youtube.com/watch?v=eFvPcwjL-m4

Sounds promising - Disappointing reaction from the market, potential upside is huge and progress being made but a naturally slow burner.

Also keeping tabs on ORPH - CEO Cathal Friel predicts 40% growth a year with 2 million of his own cash invested. Around 30 million people in Europe suffer rare diseases so huge upside. Their health databank a standout for me - GSK recently valued an Alzheimers neurologival disorder data base for £300m. CCO Maurice Treacy helps to explain the value of their patient clinical and genomic database well on recent Proactive interview https://www.youtube.com/watch?v=eFvPcwjL-m4

OXB looking set to finish off the month on a high after a solid month of growth - Open Orphan ORPH a stock also worth keeping tabs on - rises today and CEO Cathal Friel predicts 40% growth a year on recent podcast below with 2 million of his own money invested. They are currently on a presenting roadshow if anyone is interested. https://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year

Recently added - great to see ABC bouncing back over the last two days. Open Orphan ORPH doing a good job too with rises also today - CEO Cathal Friel shown serious backing with £2 million of his own money in - he predicts 40% growth a year on recent podcast. They are on presenting roadshow at the moment for those interested https://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year

Great to to see APH finishing strong after a great month. Open Orphan ORPH doing a good job too - they are on a presenting roadshow at the moment with rises also today. CEO Cathal Friel shown serious backing with £2 million of his own money in - predicts 40% growth a year on recent podcast https://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year

Looking forward to hearing how the CEO plans to turn ORPH in to a GBP 70mn market cap company, just like AMRYT

Good to see the share price rise on this weeks positive announcement. Possibly also worth looking at Open Orphan ORPH, they announced recently that they'll be engaging with the investment community at various events if you'd like to know more.

Good to see that Open Orphan will be engaging with the investment community over the next month, many investor events announced in today's RNS.